<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190411</url>
  </required_header>
  <id_info>
    <org_study_id>P010309</org_study_id>
    <nct_id>NCT00190411</nct_id>
  </id_info>
  <brief_title>Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type</brief_title>
  <official_title>Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type
      III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed
      that arteries are thin and overloaded in this patients. We test the protective effect of
      celiprolol on cardiovascular events in a 5 years, randomized, PROBE design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with verified EDS-IV syndrome are included. Patients are randomized to either
      celiprolol (50 to 400 mg BID)or no treatment. Patients who are not randomized enter a
      longitudinal survey of events. The hypothesis is a 50% reduction in the occurrence of
      cardiovascular events under treatment, assessed by a blinded, independent events committee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up</measure>
    <time_frame>during de study</time_frame>
    <description>reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness.</measure>
    <time_frame>during the study</time_frame>
    <description>Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT</condition>
  <condition>CHROMOSOME 2q31.2 DELETION SYNDROME</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celiprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celiprolol</intervention_name>
    <description>celiprolol</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>celiprolol? Dose ranging 100 to 400 mg, dose adaptation</other_name>
    <other_name>every 6 months by increment of 100 mg, based on tolerance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Untreated controls excluding betablockers</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proven disease,

          -  No betablocker at inclusion if previous CV event

        Exclusion criteria:

        Criteria of not inclusion for the RIGHTEOUS group:

          -  Patient having already presented an arterial break or a dissection and
             treated(handled) by bétâ-blocking(surrounding).

          -  Against indication in the use of CELIPROLOL:

          -  Unchecked cardiac insufficiency by the treatment

          -  cardiogenic shock

          -  BAV of 2nd and 3rd not sailed degrees

          -  angor of Prinzmetal

          -  disease of the sine

          -  bradycardia

          -  pheochromocytoma untreated

          -  low blood pressure

          -  sentimentality in the CELIPROLOL

          -  Antecedent of anaphylactic reaction

          -  myasthenia

          -  treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases,
             the patient can be included in the group followed by troop.

        Criteria of not inclusion for both groups:

          -  Refusal to participate in the study.

          -  Impossibility to move.

          -  Pregnancy

          -  Woman in age to procreate without means of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOUTOUYRIE, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arteries</keyword>
  <keyword>ultrasonography</keyword>
  <keyword>Ehlers Danlos syndrome</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>beta adrenergic antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
    <mesh_term>Abnormalities, Multiple</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Craniofacial Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

